Clinical Trial Update: SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease [Phase 3]

View source ↗

Summary

Phase 3 trial comparing SLV 308 with pramipexole for early Parkinson disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Pramipexole (pramipexole)
• SLV 308

Snippet

Sponsor: Solvay Pharmaceuticals | Conditions: Early Stage Parkinson Disease | Phase 3 | Status: COMPLETED